Hematology
News
CLL patients ‘cured’: 10 years post infusion, CAR T cells persist
A decade after CAR T’cell treatment, chronic leukemia patients reported “cured,” with cells still detectable.
News
100 coauthored papers, 10 years: Cancer transplant pioneers model 'team science'
MSKCC medical oncologists share expertise in HSCT, Spanish background, a gift for mentoring, and 100 peer-reviewed publications written together...
News
Rituximab and COVID-19 vaccines: Studies begin to answer key questions
This article aims to summarize the latest research on how rituximab affects humoral and cell-mediated response following a COVID-19 vaccine...
News
‘Highly encouraging’ MRD results for zanubrutinib add-on in CLL
Blood and bone marrow MRD was undetectable in almost 90% of subjects after a median of 10 treatment cycles.
Conference Coverage
NHL: As a second-line treatment in phase 3 trial, tisa-cel disappoints
In this phase 3 BELINDA study, CAR T-cell therapy did not prolong event-free survival as a second-line treatment of aggressive non-Hodgkin...
Conference Coverage
TKI/BiTE combo extends survival of older patients with Ph+ALL
In these elderly patients who are not candidates for chemo, the issue is whether we can prolong remission by the addition of other treatments,...
Conference Coverage
Myeloid patients respond robustly to Moderna COVID vaccine
Among 46 patients, nearly all seroconverted after second shot.
Conference Coverage
For leukemias, COVID-19 death risks tied to poor prognoses, ICU deferrals
COVID-19 death risks for acute leukemias were driven by poor physician-assessed prognoses and opting out of recommended ICU care.
News
Risk-based antenatal type-and-screen blood testing safe and economical
“In a year of selective type and screen, we saw a 51% reduction in costs related to type and screen, and a 38% reduction in overall transfusion-...
